HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Post-Pandemic Stocks

939.754

+3.8140.41%

Number of Gainers:10

Number of Losers:6

Number of Flat:1

PE:- -

High:962.137

Open:936.902

Low:936.902

Close:935.940

Volume:651.71M

Turnover:5.34B

Market Cap:633.41B

Float Cap:526.58B

Loading ...

Junshi Biosciences Reports First-Half Net Profit of RMB21.66 Million, Reversing Year-Earlier Loss

Shandong Xinhua Pharmaceutical (SEHK:719) Stock Can Margins Recover After Profit Halved

Simply Wall St.

BIOSTAR PHARM-B (02563) Reports Interim Results with Net Loss Narrowing 50.8% to RMB 26.596 Million

ACFTU Launches Second National Team Leader Competition With Ten Industry Tracks Including Rail, Power, Pharma, Machinery, Metallurgy, Building Materials, Defense Tech, ICT, Light Industry, and Textiles

Grand Pharmaceutical H1 Revenue Rises on Nuclear Medicine Demand

China's Innovative Weight-Loss Patch Receives US Clinical Trial Approval

CanSino Biologics, deepGeneAI Agree to Develop Personalized mRNA Cancer Vaccines

MT Newswires Live

China's Zhongzhi Pharmaceutical H1 Revenue Falls 10%

CSPC Pharma's Lung Cancer Candidate Meets Progression-Free Survival Primary Endpoint

MT Newswires Live

CSPC Pharma's SYS6090 (JMT108) Receives FDA Fast Track Designation for MSS/pMMR Metastatic Colorectal Cancer Treatment

CSPC Pharma Says FDA Grants Fast Track Status to Sys6090 for MSS/pMMR Metastatic Colorectal Cancer

CSPC Pharma's SYS6010 Achieves Primary Endpoint in Phase III Trial for EGFR-Mutant NSCLC Patients

CSPC Pharmaceutical - Sys6090 (Jmt108) Granted Fast Track Designation by U.S. FDA for Mss/Pmmr Mcrc

THOMSON REUTERS

Sihuan Pharma FY26 H1 Profit Attributable to Owners Rises 119% to RMB 224.7 Million; Revenue Increases 1.3% to RMB 1.16 Billion

CSPC Pharmaceutical - Sys6010 Meets Primary Endpoint of Progression-Free Survival in Phase Iii Synstar-01 Study

THOMSON REUTERS

Shanghai Junshi Biosciences Return to Profit in H1

MT Newswires Live

Sihuan Pharmaceutical Files Board, Committee Roles and Disclosure-Responsible Management List

Junshi Biosciences Swings to Profit in First-Half Results

Sinopharm Group Stock Rallies 1.1% in Hong Kong

CSPC Pharmaceutical Group Stock Rallies 1.2% in Hong Kong, Underperforms Competitors

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigermarketb.com/stock/BK1515/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"Post-Pandemic Stocks","latestPrice":939.75415,"timestamp":1787731681268,"preClose":935.94037,"halted":0,"volume":651712608,"delay":0,"changeRate":0.004075,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":3.813782,"latestTime":"08-26 16:00:00","open":936.9023,"high":962.13654,"low":936.9023,"amount":5337561096,"amplitude":0.026961,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787794200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1787707800000,1787716800000],[1787720400000,1787731200000]],"pbRate":1.404704,"peRate":17.150171,"turnoverRate":0.008657,"increases":11,"decrements":6,"flats":0,"marketCap":633405496320,"floatMarketCap":526579823360},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":962.13654,"amplitude":0.026961,"preClose":935.94037,"low":936.9023,"pbRate":"1.404704","latestPrice":939.75415,"volume":651712608,"delay":0,"open":936.9023,"prevYearClose":1190.107,"prevWeekClose":942.615,"prevMonthClose":925.972,"prevQuarterClose":802.777,"fiveDayClose":905.419,"twentyDayClose":946.773,"sixtyDayClose":944.904,"secType":"PLATE","market":"HK","turnoverRate":0.008657,"peRate":17.150171,"marketCap":633405496320,"floatMarketCap":526579823360,"timestamp":1787731681268,"nameCN":"Post-Pandemic Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":10,"down":6,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1178598132","title":"Junshi Biosciences Reports First-Half Net Profit of RMB21.66 Million, Reversing Year-Earlier Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=1178598132","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178598132?lang=en_us&edition=fundamental","pubTime":"2026-08-27 00:20","pubTimestamp":1787761218,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co., Ltd. has announced its financial results for the first half of 2026, revealing a notable turnaround in profitability.During the reporting period, the company...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK1161","01877","BK1515","688180","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662745416","title":"Shandong Xinhua Pharmaceutical (SEHK:719) Stock Can Margins Recover After Profit Halved","url":"https://stock-news.laohu8.com/highlight/detail?id=2662745416","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662745416?lang=en_us&edition=fundamental","pubTime":"2026-08-26 23:24","pubTimestamp":1787757843,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical came into this earnings print with a stock under pressure, down about 9.7% over the past month and 3.0% over the last week, even after closing at HK$5.75 on 26 August. The market has been treating the company as a low-growth, margin-challenged drug maker trading on a discounted P/E.\nThe headline this quarter is another profit squeeze. Q2 2026 revenue landed at ¥1,934.5m yet net income reached only ¥65.2m, which implies thin profitability for a pharmaceutical...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-719/shandong-xinhua-pharmaceutical-shares/news/shandong-xinhua-pharmaceutical-sehk719-stock-can-margins-rec","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-719/shandong-xinhua-pharmaceutical-shares/news/shandong-xinhua-pharmaceutical-sehk719-stock-can-margins-rec","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1515","BK1191","00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120341827","title":"BIOSTAR PHARM-B (02563) Reports Interim Results with Net Loss Narrowing 50.8% to RMB 26.596 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1120341827","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120341827?lang=en_us&edition=fundamental","pubTime":"2026-08-26 22:52","pubTimestamp":1787755941,"startTime":"0","endTime":"0","summary":"BIOSTAR PHARM-B (02563) has announced its interim results for 2026, recording revenue of RMB 36.635 million, a year-on-year increase of 147.8%. Gross profit reached RMB 34.08 million, up 147.9%...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1574","BK1161","09939","159938","02563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187289311","title":"ACFTU Launches Second National Team Leader Competition With Ten Industry Tracks Including Rail, Power, Pharma, Machinery, Metallurgy, Building Materials, Defense Tech, ICT, Light Industry, and Textiles","url":"https://stock-news.laohu8.com/highlight/detail?id=1187289311","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187289311?lang=en_us&edition=fundamental","pubTime":"2026-08-26 22:11","pubTimestamp":1787753476,"startTime":"0","endTime":"0","summary":"The All-China Federation of Trade Unions (ACFTU) General Office has issued a notice to fully launch the second National Team Leader Competition, aiming to strengthen enterprise team building, better...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","THMZ","PLTI","PLTW","JEDI","ROKT","LOUP","PLTZ","PTIR","CRTC","AMMO","BTHM","159938","DRNL","FITE","PLTA","159146","PLTU","PLOO","WAR","BK1161","PLTD","PLYY","PLTY","BK1574","BK1515","USMD","PLTL","XDEF","PLTG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662717592","title":"Grand Pharmaceutical H1 Revenue Rises on Nuclear Medicine Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=2662717592","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662717592?lang=en_us&edition=fundamental","pubTime":"2026-08-26 21:54","pubTimestamp":1787752465,"startTime":"0","endTime":"0","summary":"Grand Pharmaceutical H1 revenue rises on nuclear medicine demandOverviewHong Kong-listed pharma group's H1 revenue rose 3.2% yr/yr to HK$6.39 blnNet income attributable to owners fell to HK$1.06 bln f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL1N44N0MX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1515","03692","00512","00460","BK1593","BK1600","BK1583","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151627337","title":"China's Innovative Weight-Loss Patch Receives US Clinical Trial Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1151627337","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151627337?lang=en_us&edition=fundamental","pubTime":"2026-08-26 21:00","pubTimestamp":1787749241,"startTime":"0","endTime":"0","summary":"SBP GROUP has announced that its investigational drug CPX301, a dissolvable microneedle patch, has received a green light from the US Food and Drug Administration for clinical trials, with the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177","IE00BZ08YS42.EUR","BK1521","BK1191","BK1515","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","HK0000165453.HKD","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662160207","title":"CanSino Biologics, deepGeneAI Agree to Develop Personalized mRNA Cancer Vaccines","url":"https://stock-news.laohu8.com/highlight/detail?id=2662160207","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662160207?lang=en_us&edition=fundamental","pubTime":"2026-08-26 20:08","pubTimestamp":1787746092,"startTime":"0","endTime":"0","summary":"CanSino Biologics'  subsidiary CanSino  Biological Research entered into a strategic cooperation framework agreement with deepGeneAI to jointly develop personalized mRNA therapeutic cancer vaccines.The companies will explore combining CanSino's mRNA vaccine technology with deepGeneAI's tumor neoantigen discovery and design capabilities, according to a Wednesday Hong Kong bourse filing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4231","BK4080","BK1191","NETL","ADC","BK1515","BK1574","BK1161","06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662715194","title":"China's Zhongzhi Pharmaceutical H1 Revenue Falls 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662715194","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662715194?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:36","pubTimestamp":1787744170,"startTime":"0","endTime":"0","summary":"China's Zhongzhi Pharmaceutical H1 revenue falls 10%OverviewChina pharmaceutical maker's half-year revenue fell 10.3% yr/yrProfit attributable to owners rose 3.8% yr/yrGross profit and margin declined","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL1N44N0G0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","01681","03692","BK1600","BK1593","BK1589","BK1515","BK1606","BK1191","03737","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662718144","title":"CSPC Pharma's Lung Cancer Candidate Meets Progression-Free Survival Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2662718144","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662718144?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:56","pubTimestamp":1787741807,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group  SYS6010 met the pre-specified primary endpoint of progression-free survival as reviewed by the Independent Data Monitoring Committee.The endpoint was reached in a phase III trial testing the product as a monotherapy versus platinum-based chemotherapy for non-small cell lung cancer, according to a Wednesday Hong Kong bourse filing.According to the results, the drug candidate's progression-free survival was significantly superior to existing treatment regimens, with high efficacy and favorable safety profile.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0501845795.SGD","IE00B543WZ88.USD","LU1008478684.HKD","LU1807302812.USD","LU2039709279.SGD","LU1993786604.SGD","IE00BZ08YR35.GBP","LU0314109678.HKD","LU1152091168.USD","LU1152091754.HKD","LU1226287792.SGD","BK1515","LU1951186391.HKD","LU1226287529.USD","LU1813983027.USD","KURE","IE0008368742.USD","LU1226287875.USD","IE0008369823.USD","LU1960683339.HKD","BK1521","IE00B5MMRT66.SGD","LU1226288170.HKD","IE00BZ08YS42.EUR","SG9999004220.SGD","LU0067412154.USD","LU0072913022.USD","LU0326950275.SGD","01093","IE00B031HY20.USD","LU0315179316.USD","LU0880133367.SGD","LU1328277881.USD","LU1226288253.USD","IE00BZ08YT58.USD","HK0000165453.HKD","BK1191","LU0140636845.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119638338","title":"CSPC Pharma's SYS6090 (JMT108) Receives FDA Fast Track Designation for MSS/pMMR Metastatic Colorectal Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1119638338","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119638338?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:18","pubTimestamp":1787739482,"startTime":"0","endTime":"0","summary":"CSPC Pharma (01093) has announced that its first-in-class PD-1/IL-15 bispecific fusion protein, SYS6090 (JMT108), has been granted Fast Track designation by the U.S. Food and Drug Administration...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","LU0326950275.SGD","IE0008369823.USD","HK0000165453.HKD","MSS","LU1226287529.USD","KURE","SG9999004220.SGD","LU0315179316.USD","BK1521","LU0314109678.HKD","LU2039709279.SGD","BK1191","01093","LU1960683339.HKD","LU1152091168.USD","IE00BZ08YT58.USD","LU1951186391.HKD","IE00B543WZ88.USD","LU1813983027.USD","LU1226288170.HKD","LU0140636845.USD","LU0880133367.SGD","BK4585","IE0008368742.USD","LU0072913022.USD","IE00BZ08YS42.EUR","LU1807302812.USD","BK1515","LU0067412154.USD","IE00B031HY20.USD","LU1993786604.SGD","LU0501845795.SGD","IE00B5MMRT66.SGD","BK4113","LU1226287792.SGD","LU1226288253.USD","LU1008478684.HKD","LU1152091754.HKD","LU1226287875.USD","LU1328277881.USD","IE00BZ08YR35.GBP","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662679768","title":"CSPC Pharma Says FDA Grants Fast Track Status to Sys6090 for MSS/pMMR Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662679768","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662679768?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:11","pubTimestamp":1787739093,"startTime":"0","endTime":"0","summary":"CSPC Pharma says FDA grants Fast Track status to SYS6090 for MSS/pMMR metastatic colorectal cancerCSPC Pharmaceutical’s SYS6090 (JMT108) won US FDA Fast Track designation for MSS/pMMR metastatic color","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL2W16sV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1152091754.HKD","BK1191","IE0008369823.USD","HK0000165453.HKD","LU0067412154.USD","LU1951186391.HKD","IE00BZ08YT58.USD","BK1515","IE00B543WZ88.USD","LU1008478684.HKD","LU1226288253.USD","IE00B5MMRT66.SGD","LU2039709279.SGD","LU0501845795.SGD","LU0880133367.SGD","LU0315179316.USD","LU0072913022.USD","LU1328277881.USD","IE00BZ08YS42.EUR","BK1521","LU1813983027.USD","LU1960683339.HKD","LU1226287529.USD","KURE","01093","LU0140636845.USD","LU0314109678.HKD","LU1807302812.USD","LU1993786604.SGD","SG9999004220.SGD","LU1226287792.SGD","IE0008368742.USD","IE00BZ08YR35.GBP","LU0326950275.SGD","IE00B031HY20.USD","LU1226287875.USD","LU1152091168.USD","LU1226288170.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115485763","title":"CSPC Pharma's SYS6010 Achieves Primary Endpoint in Phase III Trial for EGFR-Mutant NSCLC Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1115485763","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115485763?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:10","pubTimestamp":1787739028,"startTime":"0","endTime":"0","summary":"CSPC PHARMA (01093) has announced that its investigational drug SYS6010 successfully met the predefined primary endpoint of progression-free survival (PFS) in the Phase III clinical study SYNSTAR-01....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","IE00B5MMRT66.SGD","LU1226288253.USD","LU0314109678.HKD","LU1813983027.USD","LU1226287529.USD","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","SG9999004220.SGD","LU0501845795.SGD","HK0000165453.HKD","01093","LU0072913022.USD","LU0140636845.USD","IE00B031HY20.USD","LU1951186391.HKD","IE00B543WZ88.USD","BK4134","IE0008368742.USD","LU0880133367.SGD","LU1152091168.USD","LU1960683339.HKD","LU1993786604.SGD","III","LU0326950275.SGD","KURE","LU1226288170.HKD","BK1515","LU1807302812.USD","LU2039709279.SGD","BK1521","LU0067412154.USD","LU1152091754.HKD","IE00BZ08YS42.EUR","LU0315179316.USD","LU1008478684.HKD","LU1226287792.SGD","LU1328277881.USD","IE0008369823.USD","LU1226287875.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662797532","title":"CSPC Pharmaceutical - Sys6090 (Jmt108) Granted Fast Track Designation by U.S. FDA for Mss/Pmmr Mcrc","url":"https://stock-news.laohu8.com/highlight/detail?id=2662797532","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662797532?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:10","pubTimestamp":1787739002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0I5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1226288170.HKD","BK1515","LU0067412154.USD","LU0140636845.USD","LU1226287792.SGD","LU2039709279.SGD","LU1152091168.USD","LU1328277881.USD","KURE","LU1152091754.HKD","IE0008369823.USD","HK0000165453.HKD","LU1993786604.SGD","IE00BZ08YT58.USD","BK1191","BK1521","LU1226287529.USD","LU1226287875.USD","SG9999004220.SGD","LU0880133367.SGD","LU1008478684.HKD","LU0315179316.USD","IE0008368742.USD","LU1951186391.HKD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","IE00BZ08YS42.EUR","LU1813983027.USD","IE00BZ08YR35.GBP","LU0072913022.USD","LU0326950275.SGD","LU1226288253.USD","01093","LU1807302812.USD","LU1960683339.HKD","LU0501845795.SGD","LU0314109678.HKD","IE00B031HY20.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662973617","title":"Sihuan Pharma FY26 H1 Profit Attributable to Owners Rises 119% to RMB 224.7 Million; Revenue Increases 1.3% to RMB 1.16 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2662973617","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662973617?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:08","pubTimestamp":1787738933,"startTime":"0","endTime":"0","summary":"Sihuan Pharma FY26 H1 profit attributable to owners rises 119% to RMB 224.7 million; revenue increases 1.3% to RMB 1.16 billionSihuan Pharmaceutical posted profit attributable to owners of RMB 224.7 m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDLc1wDYT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1515","00460","BK1191","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662792719","title":"CSPC Pharmaceutical - Sys6010 Meets Primary Endpoint of Progression-Free Survival in Phase Iii Synstar-01 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2662792719","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662792719?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:01","pubTimestamp":1787738500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0KM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1521","LU2039709279.SGD","LU1813983027.USD","LU1226288170.HKD","KURE","LU1328277881.USD","LU1993786604.SGD","LU0880133367.SGD","IE00B031HY20.USD","LU0314109678.HKD","BK1515","LU1807302812.USD","IE00B5MMRT66.SGD","IE0008369823.USD","LU0326950275.SGD","LU1960683339.HKD","LU1226287875.USD","LU1226287529.USD","IE00BZ08YS42.EUR","LU1226287792.SGD","LU1951186391.HKD","LU1226288253.USD","LU0140636845.USD","SG9999004220.SGD","IE00B543WZ88.USD","01093","LU1152091168.USD","IE0008368742.USD","LU0501845795.SGD","LU1152091754.HKD","HK0000165453.HKD","LU0067412154.USD","LU0072913022.USD","LU0315179316.USD","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","BK1191","LU1008478684.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662924367","title":"Shanghai Junshi Biosciences Return to Profit in H1","url":"https://stock-news.laohu8.com/highlight/detail?id=2662924367","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662924367?lang=en_us&edition=fundamental","pubTime":"2026-08-26 17:58","pubTimestamp":1787738304,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences  booked an attributable profit of 25.5 million yuan in the first half of 2026, returning from a loss of 413.4 million yuan a year prior, a Wednesday Hong Kong bourse filing said.Earnings per share stood at 0.02 yuan, compared with a loss per share of 0.42 yuan in the year-ago period.Revenue for the interim period increased 45% to 1.70 billion yuan from 1.17 million yuan in the corresponding period of the last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","FCA","BK1161","01877","BK1515","688180","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662794653","title":"Sihuan Pharmaceutical Files Board, Committee Roles and Disclosure-Responsible Management List","url":"https://stock-news.laohu8.com/highlight/detail?id=2662794653","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662794653?lang=en_us&edition=fundamental","pubTime":"2026-08-26 17:38","pubTimestamp":1787737093,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical files board, committee roles and disclosure-responsible management listSihuan Pharmaceutical named Che Fengsheng as chairman; Guo Weicheng as vice chairman, chief executive; exec","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL1yGHl8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","00460","BK1515","BK1600","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109069655","title":"Junshi Biosciences Swings to Profit in First-Half Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1109069655","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109069655?lang=en_us&edition=fundamental","pubTime":"2026-08-26 17:11","pubTimestamp":1787735483,"startTime":"0","endTime":"0","summary":"Junshi Biosciences (01877) has announced its interim results for the six months ended June 30, 2026, revealing a swing back to profitability with a net profit attributable to shareholders of RMB...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","01877","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662964167","title":"Sinopharm Group Stock Rallies 1.1% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2662964167","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662964167?lang=en_us&edition=fundamental","pubTime":"2026-08-26 16:33","pubTimestamp":1787733180,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. advanced 1.1% to 16.12 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.6% to 25652.97.The stock's rise snapped a two-day losing streak.Sinopharm Group Co. Ltd. closed 28% below its 52-week high of HK$22.34, which the company achieved Feb. 25.The stock outperformed some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. fell 5.7%.Trading volume totaled 5.3 million shares, compared to the 50-day average of 5.3 million shares.Data source: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1115378108.SGD","BK0239","BK0188","BK1191","BK1500","BK0183","BK0175","01099","02196","BK0028","600196","SHTDY","BK1197","BK1593","LU0640798160.USD","BK4175","BK0012","BK0196","BK1515","BK0060","BK0187","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662796413","title":"CSPC Pharmaceutical Group Stock Rallies 1.2% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2662796413","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662796413?lang=en_us&edition=fundamental","pubTime":"2026-08-26 16:33","pubTimestamp":1787733180,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of CSPC Pharmaceutical Group Ltd. advanced 1.2% to 9.53 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.6% to 25652.97.This was the stock's third consecutive day of gains.CSPC Pharmaceutical Group Ltd. closed 18% short of its 52-week high of HK$11.63, which the company achieved Sept. 9.The stock demonstrated a mixed performance when compared to some of its competitors, as Sino Biopharmaceutical Ltd. rose 2.1%, SSY Group Ltd. rose 5.2%, and United Laboratories International Holdings Ltd. fell 0.8%.Trading volume totaled 190.3 million shares, compared to the 50-day average of 100.7 million shares.Data source: Dow Jones Market Data, FactSet","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1152091754.HKD","HK0000165453.HKD","IE00B543WZ88.USD","LU0315179316.USD","LU0501845795.SGD","LU1226287792.SGD","LU1226288170.HKD","01093","KURE","LU1813983027.USD","LU1226287875.USD","IE00BZ08YR35.GBP","IE0008369823.USD","LU0072913022.USD","LU0326950275.SGD","LU1008478684.HKD","IE00B031HY20.USD","LU0314109678.HKD","LU0140636845.USD","BK1521","LU1226288253.USD","LU1328277881.USD","LU1226287529.USD","LU1993786604.SGD","IE0008368742.USD","LU1951186391.HKD","BK1191","IE00BZ08YS42.EUR","IE00B5MMRT66.SGD","LU1960683339.HKD","LU2039709279.SGD","LU1807302812.USD","SG9999004220.SGD","LU0067412154.USD","LU1152091168.USD","BK1515","IE00BZ08YT58.USD","LU0880133367.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":1,"totalSize":244,"code":"91000000","status":"200"}]}}